RxDoctor Payments Data

Robert McHale, MD

Psychiatry · Albemarle, NCNPI 1841412053

Payments from drug & device makers

$759in general payments, 2019–2025

Across 41 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$130
  • Otsuka America Pharmaceutical, Inc.$130
  • Johnson & Johnson$113
  • Indivior Inc.$84
  • AbbVie$60
  • Ironshore Pharmaceuticals Inc.$47
  • plus $195 from 8 others

What the payments were for

  • Food & beverage$65486%
  • Education$10614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$759 in reported general payments places this provider in the 65th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$34,580
Medicare patients
95
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate78$767,539
Invega SustennaPaliperidone Palmitate43$142,639
VraylarCariprazine Hcl33$59,341
RexultiBrexpiprazole27$42,038
FanaptIloperidone11$40,311
Clozapine298$24,194
TrintellixVortioxetine Hydrobromide31$24,097
Risperidone ErRisperidone Microspheres11$21,618
Atomoxetine Hcl109$13,427
Aripiprazole294$12,277
Paliperidone ErPaliperidone25$8,609
Fluvoxamine Maleate ErFluvoxamine Maleate20$7,699
PaxilParoxetine Hcl13$7,206
Risperidone318$6,525
Olanzapine OdtOlanzapine39$6,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$17$767,53978 claims
Johnson & JohnsonInvega Sustenna$113$142,63943 claims
AbbVieVraylar$60$59,34133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$130$42,03827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →